💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for BIO

No earnings history available for this symbol.

📰 Related News & Research

• iX Biopharma Ltd. 1H26 Financial Results: Revenue Decline, Improved Net Loss & No Dividend Declared for 2025 Interim Period
  February 9, 2026
  

  iX Biopharma Ltd. Interim Results Analysis – 1H FY2026 iX Biopharma Ltd., a Singapore-listed specialty pharmaceutical and nutraceutical company, released its unaudited condensed interim financial…

• TOTM Technologies Secures Additional ABIS Licences in Indonesia for National Biometric ID Enrolment 1
  February 4, 2026
  

  TOTM Technologies Secures Additional ABIS Licences in Indonesia: Key Details for Investors TOTM Technologies Secures Major Contract for 3.5 Million ABIS Licences in Indonesia Key…

• Clearbridge Health Announces Lapse of Term Sheet for Proposed Acquisition of Elpis Biopharmaceuticals
  January 23, 2026
  

  Clearbridge Health Limited: Lapse of Term Sheet for Proposed Acquisition of Elpis Biopharmaceuticals Clearbridge Health Limited Announces Lapse of Term Sheet for Proposed Acquisition of…

• iX Biopharma Recognised as One of Singapore’s Fastest Growing Companies 2026 for Third Time, Driven by WaferiX Drug Delivery Platform and US Expansion 1
  January 20, 2026
  

  iX Biopharma Ltd. (SGX-listed specialty pharmaceutical company, Co. Reg. No: 200405621W) has announced its inclusion in The Straits Times’ Singapore’s Fastest Growing Companies 2026 ranking,…

• Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Pipeline, Growth Strategies & Global Expansion (2025 Prospectus Highlights)
  January 17, 2026
  

  Baili Pharmaceutical: Hong Kong IPO Analysis, Offer Details, Financials & Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical’s Hong Kong…

• Sichuan Biokin Pharmaceutical Co., Ltd. Global Offering 2025: IPO Details, Application Process, and Key Dates Explained
  January 17, 2026
  

  Sichuan Biokin Pharmaceutical Co., Ltd. IPO Analysis: Key Investor Insights and Listing Outlook Sichuan Biokin Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Sichuan…

• Wasco Greenergy Berhad IPO 2025: Business Overview, Financial Highlights, and Market Leadership in Renewable Biomass Energy 35148158
  January 11, 2026
  

  Wasco Greenergy Berhad IPO: Investor Analysis & Outlook Company Name: Wasco Greenergy Berhad Date of Prospectus: 5 November 2025 Wasco Greenergy Berhad IPO: Growth-Driven Malaysian…

• Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Drugs, Global Expansion & Key Financials (2025)
  January 11, 2026
  

  Baili Pharmaceutical IPO Analysis: Key Details, Financials, Risks, and Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical Hong Kong IPO:…

• Sichuan Biokin Pharmaceutical Global Offering 2025: Hong Kong IPO Details, Application Process & Key Dates
  January 11, 2026
  

  Sichuan Biokin Pharmaceutical Co., Ltd. IPO Analysis Company Name: Sichuan Biokin Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Sichuan Biokin Pharmaceutical IPO: In-Depth…

• TOTM Technologies’ Subsidiary InterBio Secures Over S$6.1 Million in Indonesian National ID and Maritime Digital Contracts for 2026 1
  January 2, 2026
  

  TOTM Technologies Secures Major Indonesia Contracts Worth Over S\$6.1 Million TOTM Technologies Secures Over S\$6.1 Million in Strategic Indonesia Contracts Singapore, 2 January 2026 –…

🔍 View more Reports